The present clinical trial as a part of already published studies [28, 29] evaluated the effects of low-calorie diet (LCD) with HCA supplementation on body fat, appetite, and also serum leptin and adiponectin levels and their ratios in overweight/obese women with NAFLD. This evidence concerns the gene ADIPOQ and metabolic dysfunction-associated steatotic liver disease.